香雪製藥(300147.SZ):2024年度預虧5.996億元-8.624億元
格隆匯1月15日丨香雪製藥(300147.SZ)公佈2024年度業績預吿,2024年歸屬於上市公司股東的淨利潤虧損5.996億元–8.624億元,上年同期虧損38,896萬元;扣除非經常性損益後的淨利潤虧損5.71億元–8.34億元,上年同期虧損34,446萬元;營業收入16.13億元–20.13億元,扣除後營業收入15.86億元–19.86億元。
2024年度,公司圍繞發展戰略和年度經營目標,通過優化內部管理、大力開拓外部市場等方式努力降低市場環境對公司的影響,但面對市場競爭加劇,渠道庫存和週轉壓力加大,疊加公司流動性危機,中成藥業務銷售未達預期導致營業收入減少,毛利率下降,同時受財務費用高、重資產負擔以及計提減值準備等因素的影響,公司總體淨利潤仍處於虧損狀態。
影響公司2024年度經營業績的主要因素如下:1、公司存續的短期及長期借款金額較大,財務費用約23,000萬元。2、固定資產折舊、攤銷影響約19,000萬元。3、根據2024年末初步資產減值測試情況,預計需對存貨、在建工程、固定資產、開發支出等計提資產減值合計約30,800萬元。4、對訴訟、逾期利息等營業外支出約8,300萬元。5、預計非經常性損益對淨利潤的影響約2,900萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.